Øystein Rekdal
Chief Executive Officer presso LYTIX BIOPHARMA
Patrimonio netto: 79 132 $ in data 31/03/2024
Profilo
Øystein Rekdal is the founder of Lytix Biopharma AS, a company founded in 2003.
He holds the title of Chief Executive Officer at Lytix Biopharma AS starting in 2019.
Dr. Rekdal's current job is as a Professor at the University of Tromso.
He previously worked as a Director at Prophylix AS.
Dr. Rekdal obtained a doctorate degree from the University of Tromso.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
LYTIX BIOPHARMA AS
0.35% | 26/08/2022 | 139 963 ( 0.35% ) | 79 132 $ | 31/03/2024 |
Posizioni attive di Øystein Rekdal
| Società | Posizione | Inizio |
|---|---|---|
| LYTIX BIOPHARMA | Chief Executive Officer | 11/09/2019 |
| University of Tromso | Corporate Officer/Principal | - |
Precedenti posizioni note di Øystein Rekdal
| Società | Posizione | Fine |
|---|---|---|
Prophylix AS
 Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Director/Board Member | - |
Formazione di Øystein Rekdal
| University of Tromso | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| LYTIX BIOPHARMA | Health Technology |
| Aziende private | 1 |
|---|---|
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Health Technology |
- Borsa valori
- Insiders
- Øystein Rekdal
